Holen Sie sich die Stockscreener-App
8.96
4.19%
0.36
Handel nachbörslich:
8.64
-0.32
-3.57%
Schlusskurs vom Vortag:
$8.60
Offen:
$8.81
24-Stunden-Volumen:
1,341
Relative Volume:
0.01
Marktkapitalisierung:
$8.22M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.13M
KGV:
-0.037
EPS:
-242.0756
Netto-Cashflow:
$-14.52M
1W Leistung:
+4.43%
1M Leistung:
-6.67%
6M Leistung:
-24.07%
1J Leistung:
-30.16%
1-Tages-Spanne:
$8.742
$8.96
1-Wochen-Bereich:
$8.46
$9.44
52-Wochen-Spanne:
$6.0829
$22.03
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Firmenname
Transcode Therapeutics Inc
Sektor
Branche
Telefon
857-301-6857
Adresse
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
8.96 | 7.89M | 0 | -27.13M | -14.52M | -242.08 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Transcode Therapeutics Inc Aktie (RNAZ) Neueste Nachrichten
Responsive Playbooks and the RNAZ Inflection - Stock Traders Daily
RNAZ PE Ratio & Valuation, Is RNAZ Overvalued - Intellectia AI
TransCode Therapeutics, Inc. (RNAZ) Competitors - Meyka
RNAZ Stock Price, Quote & Chart | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
TransCode Therapeutics Delays 2025 Annual Filing - TipRanks
Bank Watch: Is TransCode Therapeutics Inc attractive for institutional investorsTrade Analysis Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
Is TransCode Therapeutics Inc attractive for institutional investorsWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
RNAZ (RNAZ) delays 2025 Form 10-K after $25M preferred placement and acquisition - Stock Titan
Growth Value: Is TransCode Therapeutics Inc showing insider buying2026 Review & Community Trade Idea Sharing Platform - baoquankhu1.vn
Gap Down: Is TransCode Therapeutics Inc subject to activist investor interestAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
Aug Volume: What are analysts price targets for TransCode Therapeutics IncDip Buying & Free High Return Stock Watch Alerts - baoquankhu1.vn
Aug Mood: Does TransCode Therapeutics Inc have pricing power2026 Pullbacks & Intraday High Probability Alerts - baoquankhu1.vn
Bond Watch: Whats the outlook for TransCode Therapeutics Incs sector2026 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Understanding the Setup: (RNAZ) and Scalable Risk - Stock Traders Daily
Portfolio Update: Will TransCode Therapeutics Inc benefit from sector rotation2026 Institutional Moves & High Win Rate Trade Tips - baoquankhu1.vn
Is TransCode Therapeutics Inc undervalued by DCF analysis2026 Spike Watch & Verified Swing Trading Watchlists - baoquankhu1.vn
Breakout Zone: Should I hold or sell TransCode Therapeutics Inc now2026 Trends & Smart Money Movement Tracker - baoquankhu1.vn
Aug Chart Watch: Is TransCode Therapeutics Inc showing insider buyingWeekly Profit Summary & Momentum Based Trading Ideas - baoquankhu1.vn
The Technical Signals Behind (RNAZ) That Institutions Follow - Stock Traders Daily
RNAZ Should I Buy - Intellectia AI
How interest rate cuts could boost TransCode Therapeutics Inc. stockWeekly Profit Analysis & Safe Swing Trade Setup Alerts - Naître et grandir
Bank Watch: Is TransCode Therapeutics Inc a good ESG investmentJuly 2025 Decliners & Risk Managed Investment Signals - baoquankhu1.vn
Aug Macro: Can TransCode Therapeutics Inc disrupt its industryJuly 2025 Chart Watch & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Weekly: Is TransCode Therapeutics Inc a speculative investmentTrend Reversal & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138 - Revista ADVFN
TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - Stocktwits
TransCode Therapeutics Expands Pipeline With Oncolytic Virus Deal - The Globe and Mail
TransCode Therapeutics (NASDAQ: RNAZ) adds Unleash oncolytic platform in all-stock licensing deal - Stock Titan
TransCode licenses bladder cancer therapy platform from Unleash - Investing.com
Precision Trading with Transcode Therapeutics Inc. (RNAZ) Risk Zones - Stock Traders Daily
TransCode Therapeutics Incenters exclusive license agreement with Unleash - marketscreener.com
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of - PR Newswire
TransCode licenses bladder cancer therapy platform from Unleash By Investing.com - Investing.com India
RNAZTransCode Therapeutics Announces Strategic Expansion of its Product Portfolio - mx.advfn.com
RNAZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TransCode Therapeutics Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules - mx.advfn.com
TransCode Therapeutics (NASDAQ:RNAZ) Shares Up 0.8% – Still a Buy? - Defense World
Fed Watch: Is TransCode Therapeutics Inc showing insider buyingPortfolio Risk Summary & Weekly Setup with High ROI Potential - baoquankhu1.vn
Buyout Rumor: Why is TransCode Therapeutics Inc stock going downEarnings Overview Report & AI Powered Market Entry Strategies - baoquankhu1.vn
Aug Gainers: Is TransCode Therapeutics Inc subject to activist investor interestMarket Growth Report & Risk Controlled Daily Trade Plans - baoquankhu1.vn
TransCode Unveils Tumor-Selective RIG-I Agonist Imaging Strategy - TipRanks
TransCode Therapeutics publishes preclinical RIG-I agonist study showing tumor-selective activation, supports TTX platform - TradingView
TransCode Therapeutics (RNAZ) highlights RIG-I cancer immunotherapy study in 8-K - Stock Titan
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development - PR Newswire
Will TransCode Therapeutics Inc. stock benefit from green energy trendsQuarterly Trade Summary & Free Reliable Trade Execution Plans - mfd.ru
Technical Reactions to RNAZ Trends in Macro Strategies - Stock Traders Daily
Technical Analysis: Whats the beta of TransCode Therapeutics Inc stockJuly 2025 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
Checkpoint Inhibitors Competitive Landscape Report 2026: Comprehensive Insights About 50+ Companies and 60+ Drugs - GlobeNewswire Inc.
Sell Signal: Can TransCode Therapeutics Inc benefit from deglobalizationCEO Change & Technical Entry and Exit Alerts - baoquankhu1.vn
Is TransCode Therapeutics Inc. stock a top momentum playJuly 2025 Decliners & Low Risk Growth Stock Ideas - mfd.ru
Can TransCode Therapeutics Inc. sustain its profitability2025 Major Catalysts & Intraday High Probability Setup Alerts - mfd.ru
Finanzdaten der Transcode Therapeutics Inc-Aktie (RNAZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):